Biodexa Pharmaceuticals Plc (BDRX) Form 424B3 — Oct 13, 2026
Biodexa Pharmaceuticals filed Prospectus Supplement No. 5 to its F-1 resale prospectus, covering 94,300 ordinary shares represented by 1,886 ADSs, and incorporating its October 8, 2026 Form 6-K. The 6-K announces an ADS ratio change from 1 ADS per 50 ordinary shares to 1 ADS per 400 ordinary shares, effective on or about October 26, 2026. ADS holders must surrender old ADSs (CUSIP 59564R872) for one new ADS (CUSIP 59564R864) for every eight old ADSs — economically a one-for-eight reverse ADS split, with ordinary shares unaffected.
Key figures
- Offering Price
- $0.3832 (last reported ADS closing price on October 12, 2026)
- Shares Offered
- 94,300 ordinary shares (1,886 ADSs) under resale prospectus
- New cusip
- 59564R864
- Old cusip
- 59564R872
- Effective date
- on or about October 26, 2026
- Reverse split ratio
- 1-for-8 reverse ADS split (new ADS ratio 1 ADS : 400 ordinary shares, up from 1 ADS : 50 ordinary shares)
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.